{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045202833792.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.510280130"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510280130"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-199807000-00030"}},{"identifier":{"@type":"NAID","@value":"30015135211"}}],"dc:title":[{"@value":"Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>The incidence of delayed hepatitis B surface antigen (HBsAg) clearance in the natural history of chronic hepatitis B virus (HBV)-infected patients was low. Previous studies regarding the prognosis in such patients were controversial. Among 1,355 chronic carriers from 1985 to 1997, spontaneous HBsAg clearance was observed in 55 patients. During a mean follow-up period of 23 months, 18 (32.7%; all were male subjects) developed serious complications, including 11 with hepatocellular carcinoma (HCC) (9 of them underwent surgical resection), 6 with cirrhosis, and 1 with subfulminant liver failure. The overall cumulative probability of complications was 29.8% at 4 years, and it was higher in males (<jats:italic toggle=\"yes\">P</jats:italic>= .044) and patients aged 45 years or more (<jats:italic toggle=\"yes\">P</jats:italic>= .006); the latter carried an 8.6-fold increased risk (95% CI: 1.2-64.6; <jats:italic toggle=\"yes\">P</jats:italic>= .037) of adverse events. Histories of acute or chronic infection by hepatitis A virus, C virus (HCV), or D virus (HDV) were present in 42% of patients. Patients seropositive for antibodies against HCV (anti-HCV) or HDV (anti-HDV) had higher alanine transaminase (ALT) levels (>40 U/L;<jats:italic toggle=\"yes\">P</jats:italic>= .008) after sero-clearance. HBV DNA was detectable in 31% of 51 subjects, in 20% of 20 with antibodies against HBsAg, in 40% of 20 with anti-HCV or anti-HDV, and also in an HCC patient’s serum and tumor. Staining of liver HBsAg was positive in 30% of 10 HCC patients. In conclusion, our results demonstrated that hepatitis B viremia may persist, and adverse complications were not rare in HBsAg-clearance patients. All such patients should be closely monitored, which may allow for earlier detection of HCC.</jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045202833793","@type":"Researcher","foaf:name":[{"@value":"Teh-ia Huo"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833792","@type":"Researcher","foaf:name":[{"@value":"Jaw-ching Wu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833795","@type":"Researcher","foaf:name":[{"@value":"Pui-ching Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833794","@type":"Researcher","foaf:name":[{"@value":"Gar-yang Chau"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833799","@type":"Researcher","foaf:name":[{"@value":"Wing-yu Lui"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833796","@type":"Researcher","foaf:name":[{"@value":"Shyh-haw Tsay"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833798","@type":"Researcher","foaf:name":[{"@value":"Ling-tan Ting"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833797","@type":"Researcher","foaf:name":[{"@value":"Full-young Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045202833800","@type":"Researcher","foaf:name":[{"@value":"Shou-dong Lee"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"1998-07","prism:volume":"28","prism:number":"1","prism:startingPage":"231","prism:endingPage":"236"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.510280130"},{"@id":"https://journals.lww.com/01515467-199807000-00030"}],"createdAt":"2004-07-27","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116408320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long‐term follow‐up study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204794896128","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of hepatocellular carcinoma who cleared hepatitis C virus with interferon therapy 13 years ago"},{"@language":"ja","@value":"Ｃ型慢性肝炎に対するインターフェロン著効１３年後に肝組織中ウイルス陰性の状態から発症した肝細胞癌の１例"},{"@value":"症例報告 C型慢性肝炎に対するインターフェロン著効13年後に肝組織中ウイルス陰性の状態から発症した肝細胞癌の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク Cガタ マンセイ カンエン ニ タイスル インターフェロン チョコウ 13ネンゴ ニ カン ソシキ チュウ ウイルス インセイ ノ ジョウタイ カラ ハッショウ シタ カン サイボウガン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204872080512","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Development of Hepatocellular Carcinoma (HCC)in a Patient 17 Years after Recovery from ChronicHepatitis B and Seroconversion to Anti-HBs"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679349240832","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fibrosis and HBV-DNA Determine the Prognosis of Chronic Hepatitis B Patients: Long-Term Follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770642688","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Development of hepatocellular carcinoma after seroclearance of hepatitis surface antigen"},{"@language":"ja","@value":"ＨＢｓ抗原陰性化後に肝細胞癌を発症したＨＢＶキャリア症例"},{"@value":"症例報告 HBs抗原陰性化後に肝細胞癌を発症したHBVキャリア症例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク HBs コウゲン インセイカ ゴ ニ カン サイボウガン オ ハッショウ シタ HBV キャリア ショウレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175489556224","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Screening for hepatocellular carcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.510280130"},{"@type":"CIA","@value":"30015135211"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.176_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.2957/kanzo.50.238_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.1111/hepr.12533_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.15369/sujms1989.15.129_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.46.1586_references_DOI_MX4cccWLgTR2M4pa7vUa9q8PYKR"}]}